Study findings in a special supplemental issue of The Pediatric Infectious Disease Journal demonstrate rotavirus vaccine's significant impact on reducing childhood diarrheal disease around the world
Source: WHO/Antonio Suarez Weise
Seattle, January 20, 2011 - Study findings in the January 2011 special supplement to The Pediatric Infectious Disease Journal demonstrate the substantial impact of rotavirus vaccines on the health of children in developed and developing countries that have introduced the vaccines.
The supplement, "Real World Impact of Rotavirus Vaccination," summarizes data on the dramatic and swift decline in the number of children hospitalized due to rotavirus in countries that include rotavirus vaccines as part of their routine immunization programs.
Second biggest childhood killer
Diarrhea is one of the top two killers of children under five years of age worldwide, and rotavirus is the leading cause of severe diarrheal disease in children. Each year, rotavirus-related diarrheal disease takes the lives of more than 500,000 children under five years of age and is responsible for the hospitalization of millions more.
"These studies add to the growing body of evidence that shows rotavirus vaccines are safe, effective, and most importantly, saving children's lives," said Dr. Anne Schuchat, director, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (CDC). "Unfortunately, too many children around the world get severely ill or die from this preventable disease. We must continue to expand our efforts to ensure that children around the world have access to these vaccines."
These studies add to the growing body of evidence that shows rotavirus vaccines are safe, effective, and most importantly, saving children's lives.
Dr. Anne Schuchat, director, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (CDC)
In 2009, the World Health Organization (WHO) recommended that all countries include rotavirus vaccines in their national immunization programs. Rotavirus vaccination is a critical part of a coordinated approach to address severe and fatal diarrhea.
Prevention and treatment of diarrhea also includes oral rehydration therapy, exclusive breastfeeding, zinc treatment, and improved hygiene and sanitation. While most children in the world will contract rotavirus by their third birthdays, children in developing countries more often die from the terrible diarrhea caused by rotavirus because treatment for severe infections is often limited or inaccessible.
"Rotavirus vaccines have enormous potential to save lives, and it is tragic that they are not more widely available to the children who need them most," said Helen Evans, interim chief executive officer of the GAVI Alliance. "We urgently need to get these life-saving vaccines to children in developing countries."
Highlights of the findings in the "Real World Impact of Rotavirus Vaccination" supplement that demonstrate rotavirus vaccine's measureable and substantial impact on children's health in both the developed and developing world include:
In the United States, there was a significant 58 to 86 percent reduction in rotavirus-related hospitalizations over three years following vaccine introduction in July 2006.
GAVI has committed to supporting rotavirus vaccine introduction in at least 40 of the world's poorest countries by 2015. The Alliance is seeking approximately US $4 billion from donors to fund the purchase of the vaccines and for other life-saving interventions.
In Australia, which introduced rotavirus vaccine in July 2007, there was a striking 89 to 94 percent reduction in rotavirus-related hospitalizations in children under five years of age living in Queensland in the two years following vaccine introduction.
In El Salvador, rotavirus hospitalization rates for children under five years of age declined dramatically by 69 to 81 percent in two and a half years following the introduction of rotavirus vaccine in October 2006.
In Mexico, which introduced rotavirus vaccine in May 2007, there was a 40 percent decline in 2009 in diarrhea-related hospitalizations in children under five years of age during the rotavirus season.
"PAHO's [Pan American Health Organization] decision to prioritize investment in rotavirus vaccines is paying off for our children," said PAHO deputy director Dr. Jon K. Andrus as he celebrated the significant impact demonstrated in Latin American countries. "The evidence is clear-immunization against rotavirus is one of the best ways to protect millions of children from severe, and often fatal, diarrhea."
The studies also show that there have been large reductions in rotavirus disease among older, unvaccinated children, suggesting that vaccination may limit the overall amount of virus transmission, thereby indirectly protecting the larger population. This phenomenon, known as "herd immunity," will require continued study.
"Wherever we look, in both the developed and developing worlds, we see a rapid and impressive reduction in rotavirus infections following the roll-out of vaccine," said Dr. John Wecker, director of the Vaccine Access and Delivery Global Program, PATH. "Vaccine effectiveness often takes years to document; with rotavirus, there is an immediate dramatic impact-one which should compel decision-makers and donors to support and implement the WHO recommendation to introduce rotavirus vaccines today."
In addition to documenting the substantial health value of rotavirus vaccination, the "Real World Impact of Rotavirus Vaccination"supplement, published December 27, 2010, also looks at changes in the duration and timing of the rotavirus season and changes in strain variation following introduction of rotavirus vaccine. Longer-term epidemiologic studies are needed to assess if and to what extent rotavirus vaccine may play a role in these changes.
# # #
To access the articles, go to http://journals.lww.com/pidj/toc/2011/01001. For background information on rotavirus and diarrheal disease, please see www.rotavirusvaccine.org and www.defeatDD.org.